The Value of 18FDG-PET/CT in Patients with Resectable Pancreatic Cancer: A Prospective Study

Stefano Crippa; Matteo Salgarello; Silvia Laiti; Stefano Partelli; Giuliano Barugola; Paola Castelli; Giuseppe Zamboni; Massimo Falconi

doi:10.6092/1590-8577/1073

Stefano Crippa Departments of Surgery, Nuclear Medicine and Pathology, “Sacro Cuore – Don Calabria” Hospital. Negrar, VR, Italy
Matteo Salgarello Departments of Surgery, Nuclear Medicine and Pathology, “Sacro Cuore – Don Calabria” Hospital. Negrar, VR, Italy
Silvia Laiti Departments of Surgery, Nuclear Medicine and Pathology, “Sacro Cuore – Don Calabria” Hospital. Negrar, VR, Italy
Stefano Partelli Departments of Surgery, Nuclear Medicine and Pathology, “Sacro Cuore – Don Calabria” Hospital. Negrar, VR, Italy
Giuliano Barugola Departments of Surgery, Nuclear Medicine and Pathology, “Sacro Cuore – Don Calabria” Hospital. Negrar, VR, Italy
Paola Castelli Departments of Surgery, Nuclear Medicine and Pathology, “Sacro Cuore – Don Calabria” Hospital. Negrar, VR, Italy
Giuseppe Zamboni Departments of Surgery, Nuclear Medicine and Pathology, “Sacro Cuore – Don Calabria” Hospital. Negrar, VR, Italy
Massimo Falconi Departments of Surgery, Nuclear Medicine and Pathology, “Sacro Cuore – Don Calabria” Hospital. Negrar, VR, Italy

DOI: https://doi.org/10.6092/1590-8577/1073

Keywords: Meeting Abstracts, Pancreas

Abstract

Context Whole-body ¹⁸fluor-deoxyglucose positron emission tomography/computed tomography (¹⁸FDG-PET/CT) has emerged as a promising diagnostic modality in different tumors. The role and the utility of ¹⁸FDG-PET/CT in resectable pancreatic cancer is debated. Objective To assess prospectively the value of ¹⁸FDG-PET/CT in addition to conventional imaging as a staging modality in candidates for resection of resectable pancreatic cancer. Methods Whole-body ¹⁸FDG-PET/CT was performed in 65 patients with pancreatic ductal adenocarcinoma who were judged resectable at high-resolution imaging. Neoadjuvant therapy was performed in the 20% of cases. Maximum standardized uptake value (SUV_max) was evaluated 60 and 250 minutes after FDG injection. Results Eight out of 65 (12%) patients were spared unwarranted resection since ¹⁸FDG-PET/CT detected synchronous advanced lung cancer (n=1) or metastatic disease (n=7). Median CA 19-9 was 53 kU/L for the entire cohort and 291 kU/L for seven patients with metastases (P=0.005). In other two patients ¹⁸FDG-PET/CT identified one colon carcinoma and a thoracic neurinoma. Thirteen out of 65 (20%) patients had low metabolic activity (SUV_max<3), and 46% of these patients had undergone neoadjuvant treatment (P=0.008). At laparotomy 3/57 (5%) patients did not undergo resection because of locally-advanced (n=1) or metastatic disease (n=2). Fifty-four patients underwent pancreatic resections associated with 11 (20%) vascular resections and one left colectomy. N1 rate was 76%, with a median of 33 resected nodes. In 8/54 (15%) patients ¹⁸FDG-PET/CT identified metastatic lymph nodes that required an extension of lymphadenectomy. Sensitivity and specificity of ¹⁸FDG-PET/CT for the detection of metastatic disease were 80% and 100%, respectively. Conclusion ¹⁸FDG-PET/CT findings resulted in changes of therapeutic management/operative procedures in one third of patients. ¹⁸FDG-PET/CT improves staging of patients with resectable pancreatic cancer. Neoadjuvant treatment is significantly associated with low metabolic activity limiting the value of ¹⁸FDG-PET/CT in this setting.

Downloads

Download data is not yet available.